Factor xii inhibitors for treating interstitial lung disease
AssigneeJustus-Liebig-Universitat Giessen
InventorsEwa Jablonska, Klaus Preissner, Malgorzata Wygrecka
Life of this patent
Estimating the term…
Abstract
The present invention provides methods for treating interstitial lung diseases, comprising administering to an individual an effective amount of an inhibitor of coagulation factor XII. The invention further provides uses and pharmaceutical kits for that treatment.
Claims17
Non-endogenous inhibitor of the cellular activity of factor XII and/or factor XIIa (FXII/FXIIa) for treating and/or preventing a fibroproliferative interstitial lung disease.
A method of treating and/or preventing fibroproliferative interstitial lung disease, comprising administering to an individual a pharmaceutically effective amount of a non-endogenous inhibitor of of the cellular activity of FXII/FXIIa.
A method of prolonging the survival time of a patient suffering from an fibroproliferative interstitial lung disease, comprising administering to said patient a pharmaceutically effective amount of a non-endogenous inhibitor of the cellular activity of FXII/FXIIa.
A pharmaceutical kit for treating interstitial lung disease, comprising a non-endogenous inhibitor of the cellular activity of FXII/FXIIa and a further drug for treating and/or preventing fibroproliferative interstitial lung disease.
Dependencies are inferred from the claim text.